Showing 1,681 - 1,700 results of 35,053 for search '(( 5 ((point decrease) OR (nn decrease)) ) OR ( 50 ((we decrease) OR (a decrease)) ))', query time: 0.93s Refine Results
  1. 1681
  2. 1682

    MK-STYX decreases RhoA activation. by Brittany M. Flowers (670483)

    Published 2014
    “…<p>(<b>A</b>) PC12 cells were transfected with pMT2 or pMT2-FLAG-MK-STYX-FLAG. 24 hr post-transfection cells were stimulated with 100 ng/ml NGF, and lysed at the indicated time points. Activation of RhoA was quantified by RhoA G-LISA small G-protein assay. …”
  3. 1683
  4. 1684
  5. 1685
  6. 1686
  7. 1687
  8. 1688

    Turning point in COVID-19 severity and fatality during the pandemic: a national cohort study in Qatar by Chemaitelly, Hiam

    Published 2023
    “…Conclusion The conclusion of the first omicron wave was a turning point in the severity of the pandemic. …”
    Get full text
    Get full text
  9. 1689
  10. 1690
  11. 1691
  12. 1692
  13. 1693

    Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

    Published 2024
    “…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
  14. 1694

    Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

    Published 2024
    “…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
  15. 1695

    Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

    Published 2024
    “…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
  16. 1696
  17. 1697
  18. 1698
  19. 1699
  20. 1700